Quantcast

Industry news that matters to you.  Learn more

Archives for August 2011

Lundbeck Canada Donates $2.7 Million to Fund Ground-breaking Depression Research

Lundbeck Canada has made a landmark donation of $2.7 million to support ground-breaking research at the University Health Network to identify biomarkers (biological markers) that will enhance the diagnosis and treatment of patients suffering from major depression and bipolar disorder.

Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.

Avantra Biosciences Corporation today announced that effective immediately it is changing its name to Courtagen Life Sciences, Inc. The company will continue to use the Avantra name for their proteomics portfolio, which includes the Avantra Biomarker System. The Avantra Biomarker System offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.

Biomarker Brief: August 26, 2011

Biomarker Brief is an occasionally recurring series highlighting particularly interesting articles on biomarkers and/or personalized medicine.

Purdue University Scientists Seek Ways to Detect Breast Cancer Earlier, with Research Funding from Susan G. Komen for the Cure

Purdue University researchers are developing a new approach to imaging that could help detect breast cancers earlier and allow doctors to tailor treatments to individuals, with funding announced today by Susan G. Komen for the Cure.

Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients

Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer patients, which includes the determination of HER2 status. Clarient and Biocept will market and sell Biocept’s new OncoCEE-BR CTC test to community hospitals, pathologists and medical oncologists. Biocept will perform the test in its laboratories, and results will be interpreted by Clarient’s highly respected pathology group (Clarient Pathology Services, Inc.). The test includes CTC enumeration and HER2 status of the detected CTCs by fluorescence in situ hybridization (FISH); it is the first commercially available CTC test to include analysis of a specific treatment-associated biomarker.